Company intelligence / Profile preview
XRad Therapeutics
Orlando, Florida, United Statesxradtx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
XRad Therapeutics’ lead candidate, XRD‑0394, is a first-in-class oral dual inhibitor of ATM and DNA-PK. It aims to enhance the effectiveness of radiation therapy in patients with metastatic, locally advanced or recurrent solid tumors. The company has initiated a Phase Ia open-label trial to evaluate safety and tolerability in combination with palliative radiation therapy at Memorial Sloan Kettering Cancer Center and Stanford Cancer Institute. Preclinical data suggest improved efficacy of radiotherapy by blocking key DNA repair enzymes[1][2][4][5]. No clinical efficacy results have been published yet.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (dual kinase inhibitors)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Aptus Clinical (CRO partner for early phase trials)[2][5]Catalyst Clinical Research (CRO support)[5]
Beyond the preview
Go deeper on XRad Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XRad Therapeutics.